Rational Pharmacotherapy in Cardiology

Advanced search

Coronary Microvascular Dysfunction: Epidemiology, Clinical Presentation, Diagnosis and Treatment


In a significant number of patients with symptoms of angina pectoris or myocardial infarction with ischemic changes in the myocardium, according to the results of instrumental research methods, there is no hemodynamically significant stenosis of the coronary arteries. In these cases, vasospastic angina or microvascular dysfunction is considered the cause of coronary heart disease. Coronary microvascular dysfunction is caused by several pathological mechanisms that cause structural and functional disorders in the microvascular bed of the heart. Clinical groups of coronary microvascular dysfunction include angina pectoris and myocardial ischemia without obstructive coronary artery disease (primary coronary microvascular dysfunction), in combination with coronary atherosclerosis, with myocardial damage and iatrogenic nature. Diagnostics of microvascular disorders is carried out on the basis of the results of non-invasive and invasive methods, which make it possible to clarify the nature of the changes and choose an effective nondrug and drug treatment. The prognosis for coronary microvascular dysfunction is poor, due to the development of cardiovascular complications and death, a high risk of disability, and a decrease in the quality of life of patients. 

About the Author

E. L. Trisvetova
Belarusian State Medical University

Eugenia L. Trisvetova,



1. Farrehi PM, Bernstein SJ, Rasak M, et al. Frequency of negative coronary arteriographic findings in patients with chest pain is related to community practice patterns. Am J Manag Care. 2002;8(7): 643-8.

2. Hasdai D, Holmes DR, Higano ST, et al. Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc. 1998;73(12):1133-40. DOI:10.4065/73.12.1133.

3. Sade LE, Eroglu S, Bozbas H, et al. Relation between epicardial fat thickness and coronary flow reserve in women with chest pain and angiographically normal coronary arteries. Atherosclerosis. 2009;204(2):580-5. DOI:10.1016/j.atherosclerosis.2008.09.038.

4. Reis SE, Holubkov R, Conrad Smith AJ, et al. Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study. Am Heart J. 2001;141(5):735-41. DOI:10.1067/mhj.2001.114198.

5. Sicari R, Rigo F, Cortigiani L, et al. Additive prognostic value of coronary flow reserve in patients with chest pain syndrome and normal or near-normal coronary arteries. Am J Cardiol. 2009;103(5):626- 31. DOI:10.1016/j.amjcard.2008.10.033.

6. Cassar A, Chareonthaitawi P, Richal SS, et al. Lack of correlation between non-invasive stress tests and invasive coronary vasomotor dysfunction in patients with non-obstructive coronary artery disease. Circ Cardiovasc Interv. 2009;2(3):237-244. DOI:10.1161/CIRCINTERVENTIONS.108.841056.

7. Wei J, Mehta PK, Johnson BD, et al. Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Interv. 2012;5(6):646-53. DOI:10.1016/j.jclin.2012.01.023.

8. Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. Circulation. 2014;129:2518-27. DOI:10/1161/CIRCULATIONAHA.113.008507.

9. Sara GD, Widmer RJ, Matsuzawa Y, et al. Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease. JACC Cardiovasc Interv. 2015;8(11):1445-53. DOI:10.1016/j.jcin.2015.06.017.

10. Mygind ND, Michelsen MM, Pena A, et al. Coronary microvascular function and cardiovascular risk factors in women with angina pectoris and no obstructive coronary artery disease: The iPOWER Study. J Am Heart Assoc. 2016;5(3):e003064. DOI:10.1161/JAHA.115003064.

11. Aribas E, Roeters van Lennep JE, Elias-Smale SE, et al. Prevalence of microvascular angina among patients with stable symptoms in the absence of obstructive coronary artery disease: a systematic review. Cardiovasc Res. 2022;118(3):763-71. DOI:10.1093/cvr/cvab061.

12. Ong P, Athanasiadis A, Borgulya GI, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation. 2014;129(17):1723-30. DOI:10.1161/CIRCULATIONAHA.113.004096.

13. Crea F, Montone RA, Rinaldi R. Pathophysiology of Coronary Microvascular Dysfunction. Circ J. 2022;86(9):1319-28. DOI:10.1253/circj.CJ-21-0848.

14. Wessel TR, Arant CB, McGorray SP, et al. Coronary microvascular reactivity is only partially by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). Clin Cardiol. 2007;30(2):69-74. DOI:10.1002/clc.19.

15. Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiologyworking group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J. 2017;38(25):1951-8. DOI:10.1093/eurhertj/ehx181.

16. Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16-20. DOI:10.1016/j.ijcard.2017.08.068.

17. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949-3003. DOI:10.1093/eurheartj/egt296.

18. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.

19. Lanza GA, De Vita A, Kaski JC. ‘Primary’ microvascular angina: clinical characteristics, pathogenesis and management. Interv Cardiol. 2018;13(3):108-11. DOI:10.15420/icr.2018.15.2.

20. Lu DY, Yalcin H, Yalcin F, et al. Stress myocardial blood flow heterogeneity is a positron emission tomography biomarker of ventricular arrhythmias in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121(9):1081-9. DOI:10.1016/j.amjcard.2018.01.022.

21. Cecchi F, Olivotto I, Gistri R, et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027-35. DOI:10.1056/NEJMoa025050.

22. Celeng C, Leiner T, Maurovich-Horvat P, et al. Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease: a meta-analysis. JACC Cardiovasc Imaging. 2019;12(7 Pt 2):1316-25. DOI:10.1016/j.jcmg.2018.07.022.

23. Godo S, Suda A, Takahashi J, et al. Coronary Microvascular Dysfunction. Arterioscler Tromb Vasc Biol. 2021;41(5):1625-37. DOI:10.1161/ATVBAHA.121.316025.

24. Montecucco F, Carbone F, Schindler TH. Pathophysiology of ST-segment elevation myocardial infarction: novel mechanisms and treatments. Eur Heart J. 2016;37(16):1268-83. DOI:10.1093/eurheartj/ehv592.

25. Padro T, Manfrini O, Bugiardini R, et al. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on ‘coronary microvascular dysfunction in cardiovascular disease. Cardiovasc Res. 2020;116(4):741-55. DOI:10.1093/cvr/cvaa003.

26. Carbon A, D’Andrea A, Sperlongano S, et al. Echocardiographic assessment of coronary microvascular dysfunction: basic concepts, technical aspects and clinical conditions. Echocardiography. 2021;38(6):993-1001. DOI:10.1111/echo.15059.

27. Chen C, Wei J, AlBadri A, et al. Coronary Microvascular Dysfunction – Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy. Circ J. 2016;81(1):3-11. DOI:10.1253/circj.CJ16-1002.

28. Xaplanteris P, Fournier S, Keulards DCJ, et al. Catheter-Based Measurements of Absolute Coronary Blood Flow and Microvascular Resistance: Feasibility, Safety, and Reproducibility in Humans. Circ Cardiovasc Interv. 2018;11(3):e006194. DOI:10.1161/CIRCINTERVENTIONS.117.006194.

29. Schindler TH, Dilsizian V. Coronary Microvascular Dysfunction: Clinical Considerations and Noninvasive Diagnosis. J Am Coll Cardiol Img. 2020;13(1 Pt 1):140-155. DOI:10.1016/j.jcmg.2018.11.036.

30. Wöhrle J, Nusser T, Merkle N, et al. Myocardial perfusion reserve in cardiovascular magnetic resonance: Correlation to coronary microvascular dysfunction. J Cardiovasc Magn Reson. 2006;8(6):781-7. DOI:10.1080/10976640600737649.

31. Zhou W, Lee JCY, Leung ST, et al. Long-Term Prognosis of Patients with Coronary Microvascular Disease Using Stress Perfusion Cardiac Magnetic Resonance. JACC Cardiovasc Imaging. 2021;14(3):602-11. DOI:10.1016/j.jcmg.2020.09.304.

32. Caliskan M, Erdogan D, Gullu H, et al. Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow. Clin Cardiol. 2007;30(9):475-9. DOI:10.1002/clc.20140.

33. Eshtehardi P, McDaniel MC, Dhawan SS, et al. Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling and microvascular function. J Invasive Cardiol. 2012;24(10):522-9.

34. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation. 2004;109(1):53-8. DOI:10.1161/01.CIR.0000100722.34034.E4.

35. Pauly DF, Johnson BD, Anderson RD, et al. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162(4):678-784. DOI:10.1016/j.ahj.2011.07011.

36. Schwartzkopff B, Brehm M, Mundchenke M, Strauer BE. Repair of Coronary Arterioles After Treatment with Perindopril in Hypertensive Heart Disease. Hypertension. 2000;36(2):220-5. DOI:10.1161/01.HYP.36.2.220.

37. Kunadian V, Chieffo A, Gamici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J. 2020;41(37):3504-20. DOI:10.1093/eurheartj/ahaa503.

38. Matsuda Y, Akita H, Terashima M, et al. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J. 2000;140(5):753-9. DOI:10.1067/mhj.2000.110093.

39. Merz CNB, Pepine CJ, Shimokawa H, Berry C. Treatment of coronary microvascular dysfunction. Cardiovasc Res 2020;116(4):856-70. DOI:10.1093/cvr/cvaa006.

40. Hazenfuss G, Mayer LS. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol. 2008;97(4):222-6. DOI:10.1007/s00392-007-0612-y.

41. Mehta PK, Goykhman P, Thomson LJ, et al. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011;4(5):514-22. DOI:10.1016/j.jcmg.2011.03.007.

42. Villano A, DiFranco A, Nerla R, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013;112(1):8-13. DOI:10.1016/j.amjcard.2013.02.045.

43. Zhu H, Xu X, Fang X, et al. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clin Ther. 2019;41(10):2137-52.e12. DOI:10.1016/j.clinthera.2019.08.008.

44. Mochri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003;41(1):15- 9. DOI:10.1016/s0735-1097(02)02632-3.

45. Del Buono MG, Montone RA, Camilli M, et al. Coronary Microvascular Dysfunction across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(13):1352-71. DOI:10.1016/j.jacc.2021.07042.

46. Juni RP, Kuster DWD, Goebel M, et al. Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin. JACC Basic Transl Sci. 2019;4(5):575-91. DOI:10.1016/j.jacbts.2019.04.003.

47. Nagayama T, Hsu S, Zhang M, et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Card. 2009;53(2):207-15. DOI:10.1016/j.jacc.2008.08.069.

48. Feliu C, Peyret H, Brassart-Pasco S, et al. Ticagrelor Prevents Endothelial Cell Apoptosis through the Adenosine Signalling Pathway in the Early Stages of Hypoxia. Biomolecules. 2020;10(5):740. DOI:10.3390/biom10050740.

49. Lerman A, Burnett JC, Higano ST, et al. Long-term L-arginine supplementation improves smallvessel coronary endothelial function in humans. Circulation. 1998;97(21):2123-8. DOI:10.1161/01.cir.97.21.2123.

50. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101(9):948-54. DOI:10.1161/01/cir.101.9.948.

51. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899-906. DOI:10.1161/01.cir.101.16.1899.

52. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: A report from the Women’s Ischemia Syndrome evaluation study and the St James Women Take Heart project. Arch Intern Med. 2009;169(9):843-50. DOI:10.1001/archinternmed.2009.50.

53. Ozcan C, Allan T, Besser SA, et al. The relationship between coronary microvascular dysfunction, atrial fibrillation and heart failure with preserved ejection fraction. Am J Cardiovasc Dis. 2021;11(1):29-38.

Supplementary files


For citations:

Trisvetova E.L. Coronary Microvascular Dysfunction: Epidemiology, Clinical Presentation, Diagnosis and Treatment. Rational Pharmacotherapy in Cardiology. 2023;19(2):186-196. (In Russ.)

Views: 288

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)